Human Macular Degeneration Peripheral Blood Mononuclear Cells

Description

Human Macular Degeneration Peripheral Blood Mononuclear Cells (AMD PBMCs) are isolated from peripheral blood of patients with clinically confirmed age-related macular degeneration (both dry and wet subtypes), representing a valuable model for studying the systemic immune components of this leading cause of vision loss. These human-derived PBMCs contain immune cell populations (activated macrophages, complement-producing B cells, and memory T cells) that demonstrate AMD-specific chronic low-grade inflammatory profiles, including activated monocytes/macrophages (CD14⁺CD16⁺), complement system dysregulation (CFH risk variants), and elevated pro-angiogenic cytokines (VEGF, IL-6), contributing to drusen formation and choroidal neovascularization. The cells exhibit typical mononuclear morphology with intact surface markers and show enhanced responsiveness to oxidative stress and drusen components, reflecting the chronic inflammatory state associated with AMD pathogenesis. These PBMCs are particularly valuable for investigating the interplay between systemic inflammation, complement dysregulation, and retinal degeneration. These PBMCs provide a powerful platform to study eye disease immune cells, analyze cytokines PBMC eye disease, perform PBMC proteomics eye conditions, evaluate strategies for macular degeneration immunotherapy, integrate genomics PBMC eye disorders, and support comprehensive PBMC characterization vision.